BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Study Summary

BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.

Conditions

Colorectal Cancer Pancreatic Cancer Gastric Cancers Cholangiocarcinoma

Interventions / Drugs

BOLD-100 +/- FOLFOX Chemotherapy (Arm VII)BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment220 participants

Primary Completion—

Lead SponsorBold Therapeutics, Inc.

Data Retrieved2026-04-11 04:08:20.398825+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.